Rx-To-OTC Switch Of Low-Cost Smoking Cessation Drug Cystine Rejected By German Committee

02 Feb 2023

Low-cost smoking cessation alternaitve cystine and azelastine-fluticasone combination nasal spray Rx-to-OTC switch applications were rejected by Germany's independent Expert Committee on Prescription at its latest meeting. Olopatadine for ophthalmic use and oral bilastine at 10mg strength were, however, given the green light.

Germany’s independent Expert Committee on Prescription, SVA, has rejected the Rx-to-OTC switch of natural nicotine replacement drug cytisine at its first 2023 meeting.

According to the short minutes of the meeting which took place on 25 January (full minutes are not expected until...